Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Non-cash Items (2020 - 2025)

Treace Medical Concepts posted quarterly Non-cash Items of $6.1 million for Q4 2025, up 10.32% year-on-year from $5.5 million in Q4 2024, and up 10.32% on a QoQ basis from $5.5 million in Q4 2024.

Treace Medical Concepts (TMCI) has 6 years of Non-cash Items data on file, last reported at $6.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 10.32% year-over-year to $6.1 million; the trailing twelve-month figure through Dec 2025 stood at $6.1 million (up 10.32% YoY), and the FY2025 full-year result was $6.1 million, up 10.32% from the prior year.
  • Non-cash Items for Q4 2025 stood at $6.1 million, up from $5.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $12.8 million in Q4 2022 and bottomed at $4.4 million in Q2 2021.
  • The 5-year median for Non-cash Items is $5.5 million (2024), against an average of $7.2 million.
  • The widest annual swing landed in 2021, when Non-cash Items surged 195.12%; it then sank 64.12% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $12.1 million in 2021, then grew by 5.79% to $12.8 million in 2022, then tumbled by 64.12% to $4.6 million in 2023, then increased by 20.6% to $5.5 million in 2024, then grew by 10.32% to $6.1 million in 2025.
  • The last three Non-cash Items figures came in at $6.1 million (Q4 2025), $5.5 million (Q4 2024), and $4.6 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Treace Medical Concepts 234.79 Mn 182.94 Mn 37.41 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 6.11 Mn
Dec 31, 2025 6.11 Mn
Dec 31, 2024 5.54 Mn
Dec 31, 2024 5.54 Mn
Dec 31, 2023 4.59 Mn
Dec 31, 2023 4.59 Mn
Dec 31, 2022 12.80 Mn
Dec 31, 2022 12.80 Mn
Dec 31, 2021 12.10 Mn
Dec 31, 2021 12.10 Mn
Sep 30, 2021 4.90 Mn
Sep 30, 2021 4.90 Mn
Jun 30, 2021 4.42 Mn
Jun 30, 2021 4.42 Mn
Dec 31, 2020 4.10 Mn
Dec 31, 2020 4.10 Mn